Group 1 - The article initiates coverage of Viatris (VTRS), a global player in the generic pharmaceutical sector, formed in 2020 through the merger of Mylan and Pfizer's Upjohn division [1] Group 2 - The company operates in developed markets and focuses on fundamental, income-oriented, long-term analysis [2] - Analysts have disclosed a beneficial long position in VTRS shares, indicating confidence in the company's performance [3]